Key Takeaways; Cannabis Sector

• Vireo Growth Acquired Hawthorne from ScottsMiracle-Gro in a Strategic Deal
• Cresco Labs and Green Thumb Industries Entered Texas as Medical Cannabis Market in the State Expanded
• Major Cannabis Multi-State Operator, The Cannabist Company, Entered Cross-Border Bankruptcy

Key Takeaways; Psychedelic Sector

• Silo Pharma Advanced PTSD Prevention Strategy with Key European Patent Milestone
• AtaiBeckley Reported Promising Phase 2a Results for Rapid-Acting Depression Therapy

Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.

Top Marijuana Companies for the Week

#1: Vireo Growth

Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) completed a transformative acquisition of The Hawthorne Gardening Company from The Scotts Miracle-Gro Company (NYSE: SMG), marking a significant step in reshaping both companies’ strategic priorities.

The transaction delivered an immediate financial boost to Vireo, adding approximately $110 million in combined cash and net working capital, alongside inventory to support operations over the next two years. In exchange, Vireo issued 213 million shares and 80 million warrants, bringing in a new strategic shareholder and strengthening its balance sheet while expanding its capabilities in cultivation supply and hydroponics.

Vireo CEO, John Mazarakis, framed the acquisition as both operational and strategic: “The acquisition of Hawthorne… creates a procurement platform to optimize supply chain management and drive cost efficiency across our portfolio,” he said, adding that the partnership “strengthens the Vireo balance sheet” and positions the company for long-term value creation.

From the seller’s perspective, Scotts Miracle-Gro emphasized focus and discipline in their press release. Chairman and CEO Jim Hagedorn said, “The divestiture of Hawthorne demonstrates further progress toward our strategy to drive long-term growth in our core lawn and garden business,” noting that removing Hawthorne will support margin recovery and operational efficiency targets. Furthermore, he added that the company has “found a good home” for Hawthorne, which will preserve its future upside while allowing Scotts to refocus on its core consumer segment.

The deal also deepened ties between the two companies. Chris Hagedorn, who previously led Hawthorne, was nominated to join Vireo’s board and is expected to play a key role in shaping future growth initiatives. He expressed confidence in the transition, stating that “Hawthorne fits naturally within Vireo’s platform,” and highlighting Vireo’s “strong leadership and a solid balance sheet” to execute on its ambitions.

For Vireo, the acquisition enhances its footprint across the cannabis supply chain, complementing its operations in major U.S. markets. For Scotts Miracle-Gro, the divestiture sharpens its focus on its core lawn and garden business while maintaining indirect exposure to Hawthorne’s potential through its investment stake.

#2: Cresco Labs

Two major U.S. cannabis operators, Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) and Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), secured conditional entry into Texas’ rapidly evolving medical marijuana market, signaling a pivotal moment for the state’s long-restricted cannabis sector.

The companies were awarded licenses under Phase II of the Texas Compassionate Use Program (TCUP), which is part of a broader expansion that will increase the number of vertically integrated operators in the state to fifteen. The move follows legislative changes signed by governor of Texas, Greg Abbott, in 2025, which widened patient eligibility and allowed access to low-dose THC products; measures expected to significantly boost demand.

For Cresco Labs, the license represents a strategic foothold in one of the largest untapped medical cannabis markets in the United States. In a press release, the company’s CEO, Charlie Bachtell, emphasized both patient impact and operational strength, stating: “Texas patients deserve access to consistent, quality medicine, and we’re excited to deliver it.” He added that the win “points to Cresco Labs’s deep regulatory expertise and thoughtful approach to meaningful local engagement,” while highlighting the company’s ability to scale efficiently through disciplined expansion.

Green Thumb Industries, which operates a broad national retail footprint, joins Cresco in targeting Texas’ growing patient base, which surpassed 135,000 in 2025 but still represents a small fraction of the state’s roughly 30 million residents: leaving significant room for growth.

Despite the milestone, the licenses remain conditional. The Texas Department of Public Safety will conduct further financial and regulatory reviews before granting final approval. Companies must also become operational within 24 months or risk losing their permits.

The expansion highlight Texas’ emergence as a key battleground for multistate operators; Green Thumb and Cresco Labs now joining earlier entrants such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) and Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO), which were among the first 9 companies granted preliminary approval to grow Texas medicinal marijuana program in December 2025. With regulatory barriers easing and patient access increasing, the state is poised to become one of the most significant growth markets in U.S. medical cannabis.

#3: The Cannabist Company

The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) initiated a sweeping restructuring effort, filing for bankruptcy protection in the United States while simultaneously commencing creditor proceedings in Canada, marking one of the most consequential financial collapses in the modern cannabis industry.

The cannabis multi-state operator (MSO), which was once a prominent player in U.S. cannabis markets, filed under Chapter 15 in Delaware following its March 24 announcement that it would pursue court-supervised restructuring under Canada’s Companies’ Creditors Arrangement Act (CCAA). The dual-track process is designed to stabilize operations, complete asset sales, and enable what the company describes as an “orderly wind-down” of non-core markets.

Company leadership said it had explored “a range of options… including potential asset sales, mergers, or other strategic and financial transactions,” but concluded that formal restructuring was unavoidable “in light of persistent operational and financial challenges facing both the Company and the broader industry.”

At the center of the restructuring was an aggressive divestment strategy. The Cannabist had already completed the sale of its Virginia assets for $130 million and struck definitive agreements to sell assets in Ohio and Delaware for a combined $63.5 million in cash and notes. Additional negotiations were underway to offload operations across several states, including Illinois, New Jersey, Colorado, Massachusetts, Maryland, and West Virginia.

Despite these efforts, the company remained burdened by approximately $270 million in outstanding obligations to lenders and tax authorities. The financial strain, coupled with projected negative cash flow, had forced The Cannabist to abandon certain markets altogether.

Operations in New York have been fully ceased, with the company surrendering its medical cannabis license, while activities in Pennsylvania are being wound down after failing to attract viable buyers. Court filings noted that “substantially all” inventory in Pennsylvania had already been liquidated.

The restructuring is being carried out with the support of key creditors, including noteholders representing more than 60% of the company’s secured debt, providing a critical foundation for executing the asset sales and legal proceedings.

The Cannabist’s case is particularly significant because it tests the viability of U.S. bankruptcy protections for cannabis companies, which operate in a complex legal environment due to federal prohibition. By leveraging Chapter 15, which is typically used for foreign entities, the company is attempting to bridge its Canadian incorporation with its U.S.-based operations.

Industry observers suggest the move could set a precedent. As one legal expert noted, heavily leveraged cannabis firms are increasingly struggling to service debt, and creditor tolerance is waning across the sector.

Beyond its financial implications, this bankruptcy may reshape market dynamics in tightly regulated states. In Maryland, for example, the potential sale of The Cannabist’s licenses could create a rare entry point into a restricted market, pending regulatory approval.

Top Psychedelic Companies for Week

#1: Silo Pharma

Silo Pharma, Inc. (NASDAQ: SILO) took a significant step forward in its effort to reshape the treatment of stress-related disorders, announcing that the European Patent Office intends to grant a patent covering its novel preventative therapy targeting the serotonin 4 (5-HT4) pathway.

The patent, which is licensed exclusively from Columbia University, outlines methods designed to prevent stress-induced fear, depressive-like behavior, and related psychiatric conditions. Unlike conventional treatments that focus on managing symptoms after onset, Silo’s approach targets biological pathways linked to stress resilience, positioning it as a proactive strategy for disorders such as PTSD.

Silo Pharma Chief Executive Officer, Eric Weisblum, emphasized the importance of the development, stating, “This is a high-value milestone that strengthens our global intellectual property position and underscores the potential of our 5-HT4 program.” He added that the company sees the therapy as “a compelling shift toward proactive treatment of stress-related disorders,” highlighting the scale of unmet need in the mental health space.

The patent protection, once formally granted, is expected to extend across major European markets. Silo Pharma stated that it is also assessing Unitary Patent protection and national validation strategies to broaden its geographic reach and long-term commercial value.

Investor response was immediate, with shares of the company surging sharply on Tuesday following the announcement, reflecting growing confidence in its differentiated pipeline and intellectual property strategy. The development further reinforced Silo’s focus on next-generation central nervous system therapies, including programs targeting PTSD, chronic pain, and neurodegenerative diseases.

As global attention intensifies around mental health, Silo Pharma’s preventative model may signal a broader shift in how stress-related conditions are addressed, moving from reactive care toward early intervention and resilience-building treatments.

#2: AtaiBeckley

AtaiBeckley Inc. (NASDAQ: ATAI) announced encouraging new clinical data highlighting the potential of its investigational treatment BPL-003 for patients with treatment-resistant depression (TRD). The peer-reviewed Phase 2a results, published in CNS Drugs, show that a single intranasal dose of the therapy can deliver both rapid and sustained antidepressant effects, even in patients continuing standard Selective Serotonin Reuptake Inhibitors (SSRI) treatment.

According to AtaiBeckley, the study found that 66.7% of participants experienced a significant antidepressant response just two days after receiving a single dose of BPL-003, across both 10 mg and 12 mg groups. Notably, these improvements proved durable: after 12 weeks, 83% of patients in the 10 mg group and 66.7% in the 12 mg group maintained their response. Participants also showed marked reductions in depression severity scores, with some reaching levels consistent with remission.

Safety and practicality were key highlights. The company reported that BPL-003 was generally well tolerated, with no serious adverse events reported. Most side effects were mild and resolved the same day, and patients were ready for discharge roughly 100 minutes after dosing; supporting the treatment’s feasibility in real-world clinical settings.

Srinivas Rao, Chief Executive Officer of AtaiBeckley emphasized the significance of the findings, stating: “A 66.7% Day-2 response rate with a single intranasal dose of BPL-003, represents a compelling clinical signal in patients who remained on their baseline SSRI therapy. These Phase 2a data reinforce the potential of BPL-003 to transform the treatment paradigm for TRD as we prepare to initiate Phase 3 in Q2 2026”.

Chief Medical Officer at AtaiBeckley, Kevin Craig, added that the study demonstrates compatibility with existing antidepressant regimens: “This study provides the first Phase 2a evidence that BPL-003 can be administered alongside SSRIs without compromising efficacy or safety,” he said, noting that the short treatment duration and quick recovery time could ease integration into psychiatric care.

BPL-003, which is an intranasal formulation of mebufotenin benzoate, has already received Breakthrough Therapy Designation from the U.S. FDA, underscoring its potential importance. With Phase 3 trials on track to begin in the second quarter of 2026, AtaiBeckley is positioning the therapy as a possible breakthrough for the millions of patients worldwide who do not respond to conventional antidepressants.